MLYS · Mineralys Therapeutics, Inc.
$27.52
+0.81 (+3.03%)
At close · Jul 21
Market Cap
$2.27B
Shares
82.50M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$154.65M
+13%
FY2025
Diluted EPS
-$2.29
+37.4%
FY2025
Operating Cash Flow
-$142.42M
+14.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $118.5M | $132.01M | $168.58M | $70.36M | $26.25M | |
| $53M | $38.6M | $23.82M | $14.3M | $5.23M | |
| — | $59K | $43K | $0 | — | |
| $171.5M | $170.6M | $192.4M | $84.66M | $31.48M | |
| -$171.5M | -$170.6M | -$192.4M | -$84.66M | -$31.48M | |
| $19.72M | $15.95M | $14.59M | $12.76M | $1.68M | |
| — | $0 | — | — | — | |
| -$151.78M | -$154.65M | -$177.81M | -$71.9M | -$29.8M | |
| USD/shares | — | -$2.29 | -$3.66 | -$1.99 | -$5.77 |
| USD/shares | — | -$2.29 | -$3.66 | -$1.99 | -$5.77 |
| shares | — | 67.66M | 48.54M | 36.19M | 5.17M |
| shares | — | 67.66M | 48.54M | 36.19M | 5.17M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
13 filings
13 filers
Visit website
Investor relations